Preservation of fertility and subsequent childbirth after methotrexate treatment of placenta percreta: a case report.
BACKGROUND
Placenta percreta is associated with maternal morbidity and mortality. A hysterectomy is often needed to control the bleeding in such cases. However, it has been advocated that placenta percreta be managed conservatively to avoid massive pelvic bleeding and to preserve the patient's fertility. Here, we present a case of placenta percreta diagnosed by magnetic resonance imaging, and treated with systemic administration of methotrexate.


METHODS
A 27-year-old nulliparous Japanese woman at 39 gestational weeks had an uncomplicated vaginal delivery of a 3244-g infant. However, her placenta was not delivered, and we could not remove it manually. Contrast-enhanced magnetic resonance imaging indicated deep myometrial invasion by placental tissue and the whole placenta was strongly enhanced. Seven days post-partum, her serum human chorionic gonadotropin level was 12,656IU/L. Our patient hoped to preserve her uterus for a future pregnancy. She therefore received 13 courses of methotrexate (50mg/week, intravenous injection). Her serum human chorionic gonadotropin level was undetectable 97 days after the first methotrexate injection. At 117 days post-partum, she had a labor-like pain every three minutes and delivered the placenta. Our patient regained normal menses and at follow-up remained in good health. Two years later, she delivered a healthy daughter.


CONCLUSIONS
We should try to detect placenta percreta in high-risk patients by any means. For low-risk patients, we should give a diagnosis swiftly and control any intrauterine infection and massive bleeding.
Department of Obstetrics and Gynecology, Sapporo Medical University Hospital, South 1, West 16, Chuo-ku, Sapporo, Hokkaido, 060-8543, Japan. mtamate@sapmed.ac.jp.
Masato
M
Tamate
Department of Obstetrics and Gynecology, Sapporo Medical University Hospital, South 1, West 16, Chuo-ku, Sapporo, Hokkaido, 060-8543, Japan.
Motoki
M
Matsuura
Department of Obstetrics and Gynecology, Sapporo Medical University Hospital, South 1, West 16, Chuo-ku, Sapporo, Hokkaido, 060-8543, Japan.
Shutaro
S
Habata
Department of Obstetrics and Gynecology, Sapporo Medical University Hospital, South 1, West 16, Chuo-ku, Sapporo, Hokkaido, 060-8543, Japan.
Yushi
Y
Akashi
Department of Obstetrics and Gynecology, Sapporo Medical University Hospital, South 1, West 16, Chuo-ku, Sapporo, Hokkaido, 060-8543, Japan.
Ryoichi
R
Tanaka
Department of Obstetrics and Gynecology, Sapporo Medical University Hospital, South 1, West 16, Chuo-ku, Sapporo, Hokkaido, 060-8543, Japan.
Shinichi
S
Ishioka
Department of Obstetrics and Gynecology, Sapporo Medical University Hospital, South 1, West 16, Chuo-ku, Sapporo, Hokkaido, 060-8543, Japan.
Toshiaki
T
Endo
Department of Obstetrics and Gynecology, Sapporo Medical University Hospital, South 1, West 16, Chuo-ku, Sapporo, Hokkaido, 060-8543, Japan.
Tsuyoshi
T
Saito
D000328:Adult; D006063:Chorionic Gonadotropin / Q000097:blood; D005260:Female; D005298:Fertility / Q000502:physiology; D006801:Humans; D008279:Magnetic Resonance Imaging; D008727:Methotrexate / Q000008:administration & dosage*; D010120:Oxytocics / Q000008:administration & dosage*; D010921:Placenta Accreta / Q000175:diagnosis* / Q000188:drug therapy*; D049590:Postpartum Period; D011247:Pregnancy; D047929:Term Birth
D006063:Chorionic Gonadotropin; D010120:Oxytocics; D008727:Methotrexate